OTC:MLSPF

Melrose Industries PLC (OTC: MLSPF) Delivers Strong H1 2026 Financial Results Despite Operational Setback

Font: Financial Modeling Prep  • Aug 02, 2026

Market Chart
  • Melrose Industries reported robust financial performance for the first half of 2026, exceeding market expectations for both earnings per share (EPS) and revenue.
  • The company demonstrated strong financial health with positive free cash flow and manageable net debt, indicating efficient operations.
  • An operational incident at its Garden Grove facility led to significant exceptional costs and a temporary pause in its share buyback program, impacting recent stock performance.

Melrose Industries PLC (OTC: MLSPF) is a British manufacturing company specializing in the aerospace and defense sectors. The company recently reported its financial results for the first half of 2026, showing strong performance that surpassed market expectations. This robust performance stems from high demand in its key markets.

On July 31, 2026, Melrose Industries announced an earnings per share (EPS) of $0.23. Its revenue reached $2.48 billion, beating the consensus estimate of $2.41 billion. This impressive revenue growth was supported by a 10% increase in group revenue and a 16% surge in operating profit to nearly £350 million.

The company's financial health shows positive signs. Melrose Industries generated a positive free cash flow of £13 million, a significant £67 million improvement from the previous year. Free cash flow is the cash a company has left after paying for its operations and investments. Melrose Industries' net debt stood at £1.53 billion, or 1.8 times its earnings.

However, an incident at Melrose Industries' Garden Grove facility in California creates some operational uncertainty. As highlighted by Proactive Investors, the company expects exceptional costs of £25 million to £30 million due to this event. The incident has already reduced first-half revenue by £16 million and adjusted operating profit by £9 million.

Following the news, Melrose Industries' shares fell by 3.5%, trading at 458.80p. The company has also paused its £175 million share buyback program to evaluate the financial impact. Despite these challenges, the stock has a trailing price-to-earnings (P/E) ratio of 35.44, a key metric used to value a company by its profits.

Market Overview
ADGM
Adagio Medical Holdings, Inc.
$0.80
73.91%
TNMG
TNL Mediagene
$0.48
33.06%
ENSC
Ensysce Biosciences, Inc.
$0.38
37.17%
PLTR
Palantir Technologies Inc.
$162.66
29.45%
SXTC
China SXT Pharmaceuticals, Inc.
$0.12
60.08%
NVDA
NVIDIA Corporation
$211.94
2.56%
QNME
Lakeside Holding Limited
$0.69
-37.59%
AMIX
Autonomix Medical, Inc.
$19.50
434.25%
INTC
Intel Corp.
$100.86
10.84%
VTGN
VistaGen Therapeutics, Inc.
$0.30
22.45%